As an extension of this previously published work [14], this report focused on expanded studies of the effects of the panRAF inhibitor LY3009120 on a multitude of preclinical models of human CRC harboring activating mutations in the KRAS or BRAF genes, including investigation of the effects of LY3009120 on downstream effectors of the RAS/RAF pathway additional to MEK/ERK/RSK. The gene discussed is MAP2K7; the disease is colorectal carcinoma.